Neuromyelitis optica and pregnancy during therapeutic B cell depletion: Infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1544-1547

  Ringelstein, M ^a   Harmel, J ^a   Distelmaier, F ^b   Ingwersen, J ^a   Menge, T ^a   Hellwig, K ^c   Kieseier, B ^a   Mayatepek, E ^b   Hartung, H P ^a   Kuempfel, T ^d   Aktas, O ^a  

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

antibody transfer; Neuromyelitis optica; pregnancy; relapse prevention; rituximab

Indexed keywords

AQUAPORIN 4 ANTIBODY; RITUXIMAB; STEROID;

ADULT; ARTICLE; BLADDER DYSFUNCTION; BLINDNESS; CASE REPORT; CESAREAN SECTION; CYSTITIS; DISEASE ACTIVITY; DRUG MEGADOSE; ENDOMETRITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; RADIOIMMUNOPRECIPITATION; RELAPSE; SPASTIC PARAPLEGIA; UMBILICAL CORD BLOOD;

ANTIBODY TRANSFER; NEUROMYELITIS OPTICA; PREGNANCY; RELAPSE PREVENTION; RITUXIMAB;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; FEMALE; FETAL BLOOD; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; LYMPHOCYTE DEPLETION; NEUROMYELITIS OPTICA; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; YOUNG ADULT;

EID: 84884540855     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513498125     Document Type: Article

References (13)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 ; 6: 805-815
2. Bourre B, Marignier R, Zephir H, et al. Neuromyelitis optica and pregnancy. Neurology. 2012 ; 78: 875-879
3. Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012 ; 78: 1264-1267
4. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998 ; 339: 285-291
5. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008 ; 65: 1443-1448
6. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011 ; 68: 1412-1420
7. Pellkofer HL, Suessmair C, Schulze A, et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009 ; 15: 1006-1008
8. Menge T, Cree B, Saleh A, et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012 ; 79: 285-287
9. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success. Mult Scler. 2012 ; 18: 1022-1026
10. Trowsdale J, Betz AG. Mother's little helpers: Mechanisms of maternal-fetal tolerance. Nat Immunol. 2006 ; 7: 241-246
11. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008 ; 131: 3072-3080
12. Chanson JB, de Seze J, Eliaou JF, et al. Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker?. Lupus. 2013 ; 22: 229-232
13. Lefvert AK, Osterman PO. Newborn infants to myasthenic mothers: A clinical study and an investigation of acetylcholine receptor antibodies in 17 children. Neurology. 1983 ; 33: 133-138